Methadone in cancer pain management: individualize dose and titrate to effect
KM Foley and RW Houde
JCO Oct 1 1998: 3213–3215. [PDF]
	Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
	C Ripamonti, L Groff, C Brunelli, D Polastri, A Stavrakis, and F De Conno
	JCO Oct 1 1998: 3216–3221. [Abstract] [PDF]
	Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain
	E Bruera, M Belzile, E Pituskin, R Fainsinger, A Darke, Z Harsanyi, N Babul, and I Ford
	JCO Oct 1 1998: 3222–3229. [Abstract] [PDF]
	Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain
	R Kaplan, WC Parris, ML Citron, D Zhukovsky, RF Reder, BJ Buckley, and RF Kaiko
	JCO Oct 1 1998: 3230–3237. [Abstract] [PDF]
	Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
	JM Christie, M Simmonds, R Patt, P Coluzzi, MA Busch, E Nordbrock, and RK Portenoy
	JCO Oct 1 1998: 3238–3245. [Abstract] [PDF]
	Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
	GL DeNardo, SJ DeNardo, DS Goldstein, LA Kroger, KR Lamborn, NB Levy, JP McGahan, Q Salako, S Shen, and JP Lewis
	JCO Oct 1 1998: 3246–3256. [Abstract] [PDF]
	CAMPATH-1H monoclonal antibody in therapy for previously treated low- grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma
	J Lundin, A Osterborg, G Brittinger, D Crowther, H Dombret, A Engert, A Epenetos, C Gisselbrecht, D Huhn, U Jaeger, J Thomas, R Marcus, N Nissen, C Poynton, E Rankin, R Stahel, M Uppenkamp, R Willemze, and H Mellstedt
	JCO Oct 1 1998: 3257–3263. [Abstract] [PDF]
	Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
	C Guglielmi, F Gomez, T Philip, A Hagenbeek, M Martelli, C Sebban, N Milpied, D Bron, JY Cahn, R Somers, P Sonneveld, C Gisselbrecht, H Van Der Lelie, and F Chauvin
	JCO Oct 1 1998: 3264–3269. [Abstract] [PDF]
	Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue
	SY Liu, JF Eary, SH Petersdorf, PJ Martin, DG Maloney, FR Appelbaum, DC Matthews, SA Bush, LD Durack, DR Fisher, TA Gooley, ID Bernstein, and OW Press
	JCO Oct 1 1998: 3270–3278. [Abstract] [PDF]
	Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
	J Cortes, M Talpaz, S O'Brien, MB Rios, A Majlis, M Keating, EJ Freireich, and H Kantarjian
	JCO Oct 1 1998: 3279–3285. [Abstract] [PDF]
	Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
	SB Bordow, MD Norris, PS Haber, GM Marshall, and M Haber
	JCO Oct 1 1998: 3286–3294. [Abstract] [PDF]
	High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study
	F Pein, J Michon, D Valteau-Couanet, E Quintana, D Frappaz, JP Vannier, T Philip, C Bergeron, MC Baranzelli, A Thyss, JL Stephan, P Boutard, JC Gentet, JM Zucker, MF Tournade, and O Hartmann
	JCO Oct 1 1998: 3295–3301. [Abstract] [PDF]
	Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study
	RC Lilenbaum, AA Miller, G Batist, S Bernard, DR Hollis, GL Rosner, MJ Egorin, RL Schilsky, and MJ Ratain
	JCO Oct 1 1998: 3302–3309. [Abstract] [PDF]
	Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study
	KA Jaeckle, HJ Eyre, JJ Townsend, S Schulman, HM Knudson, M Belanich, DB Yarosh, SI Bearman, DJ Giroux, and SC Schold
	JCO Oct 1 1998: 3310–3315. [Abstract] [PDF]
	Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
	H Choy, W Akerley, H Safran, S Graziano, C Chung, T Williams, B Cole, and T Kennedy
	JCO Oct 1 1998: 3316–3322. [Abstract] [PDF]
	Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer
	N Murray, C Grafton, A Shah, K Gelmon, E Kostashuk, E Brown, C Coppin, A Coldman, and R Page
	JCO Oct 1 1998: 3323–3328. [Abstract] [PDF]
	Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer
	N Masuda, K Matsui, S Negoro, N Takifuji, K Takeda, T Yana, M Kobayashi, T Hirashima, Y Kusunoki, S Ushijima, I Kawase, T Tada, H Sawaguchi, and M Fukuoka
	JCO Oct 1 1998: 3329–3334. [Abstract] [PDF]
	Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma
	LS Hofstra, GB Kristensen, PH Willemse, A Vindevoghel, H Meden, M Lahousen, F Oberling, B Sorbe, M Crump, I Sklenar, WJ Sluiter, B Kiese, CG Trope, and EG de Vries
	JCO Oct 1 1998: 3335–3344. [Abstract] [PDF]
	Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
	MA Bookman, H Malmstrom, G Bolis, A Gordon, A Lissoni, JB Krebs, and SZ Fields
	JCO Oct 1 1998: 3345–3352. [Abstract] [PDF]
	Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
	AD Seidman, CA Hudis, J Albanel, W Tong, I Tepler, V Currie, ME Moynahan, M Theodoulou, M Gollub, J Baselga, and L Norton
	JCO Oct 1 1998: 3353–3361. [Abstract] [PDF]
	A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
	V Valero, SE Jones, DD Von Hoff, DJ Booser, RG Mennel, PM Ravdin, FA Holmes, Z Rahman, MW Schottstaedt, JK Erban, L Esparza-Guerra, RH Earhart, GN Hortobagyi, and HA Burris, 3rd
	JCO Oct 1 1998: 3362–3368. [Abstract] [PDF]
	Phase II trial of liposomal daunorubicin in the treatment of AIDS- related pulmonary Kaposi's sarcoma
	A Tulpule, RC Yung, J Wernz, BM Espina, A Myers, DT Scadden, S Cabriales, M Ilaw, W Boswell, and PS Gill
	JCO Oct 1 1998: 3369–3374. [Abstract] [PDF]
	Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions
	GJ Cook, S Houston, R Rubens, MN Maisey, and I Fogelman
	JCO Oct 1 1998: 3375–3379. [Abstract] [PDF]
	Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three- dimensional conformal radiotherapy
	MJ Zelefsky, O Lyass, Z Fuks, T Wolfe, C Burman, CC Ling, and SA Leibel
	JCO Oct 1 1998: 3380–3385. [Abstract] [PDF]
	Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors
	C Kollmannsberger, J Beyer, JP Droz, A Harstrick, JT Hartmann, P Biron, A Flechon, P Schoffski, M Kuczyk, HJ Schmoll, L Kanz, and C Bokemeyer
	JCO Oct 1 1998: 3386–3391. [Abstract] [PDF]
	Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study
	L Sengelov, C Kamby, B Lund, and SA Engelholm
	JCO Oct 1 1998: 3392–3397. [Abstract] [PDF]
	Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
	NA Dawson
	JCO Oct 1 1998: 3398–3405. [Abstract] [PDF]
	Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer
	M Benevolo, M Mottolese, M Cosimelli, M Tedesco, D Giannarelli, S Vasselli, M Carlini, A Garofalo, and PG Natali
	JCO Oct 1 1998: 3406–3411. [Abstract] [PDF]
	Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group
	GD Demetri, M Kris, J Wade, L Degos, and D Cella
	JCO Oct 1 1998: 3412–3425. [Abstract] [PDF]
	Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment
	KA Semb, S Aamdal, and P Oian
	JCO Oct 1 1998: 3426–3432. [Abstract] [PDF]
Scientific misconduct in cancer clinical trials
EJ Emanuel and WB Patterson
JCO Oct 1 1998: 3433–3438. [PDF]
	Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women
	R Fossati, C Confalonieri, V Torri, E Ghislandi, A Penna, V Pistotti, A Tinazzi, and A Liberati
	JCO Oct 1 1998: 3439–3460. [Abstract] [PDF]
	Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer
	A Sulkes, SE Benner, and RM Canetta
	JCO Oct 1 1998: 3461–3475. [Abstract] [PDF]
Pneumocystis carinii pneumonia with peripheral nodular infiltrates in a patient with T-acute lymphoblastic leukemia
GG Wulf, U Reichard, B Wormann, and W Hiddemann
JCO Oct 1 1998: 3476–3477. [PDF]
An open letter to the American Society of Clinical Oncology
S Green, J Crowley, B Blumenstein, and J Benedetti
JCO Oct 1 1998: 3478a. [PDF]
Posttransplant Kaposi's sarcoma treated with paclitaxel
CJ Wu and DT Scadden
JCO Oct 1 1998: 3478b–3479. [PDF]
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer
GV Scagliotti, A Gregor, and G Giaccone
JCO Oct 1 1998: 3479–3480. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.